AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.
SENSEX 77,139.40
NIFTY 24,079.15
CRUDEOIL 7,722.00
+ 362.00
GOLD 141,385.00
AstraZeneca to take rights to Dizal's lung cancer pill for $600M upfront
AstraZeneca pays up to $1.5B for EGFR lung cancer drug Zegfrovy from its spinoff Dizal
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
AstraZeneca fecha acordo de até US$ 1,5 bilhão por medicamento contra câncer de pulmão
AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and…
The company’s core earnings for the three months ended June 30 rose 18% to $2.63 per share, while total revenue jumped 5% to…
Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is
Zydus and Apollo Hospitals collaborate to enhance access to a multi-cancer blood test for early detection in India.
The merger expands the combined entity’s manufacturing, research, and development capabilities, with a focus on specialty drugs…
Zydus receives USFDA approval for a surgical imaging drug, Indocyanine Green, with a 180-day exclusivity window for marketing.
